Efflux-agnostic therapy for mesenchymal TNBC
Some tumours pump out every drug. Use treatments the pumps cannot touch: radiation, radioligands, immune cells, and payloads designed to evade them.
The mesenchymal/claudin-low TNBC subtype and post-chemotherapy residual disease often show high ABCB1/ABCG2. MMAE, DXd, and SN-38 are all substrates. A rational strategy prioritises efflux-independent modalities.
Pages like this
not linked directly; found by shared links- TermT030 (belotecan derivative)
Shares Drug efflux pumps (ABC transporters), Sacituzumab tirumotecan, Antibody-drug conjugate (ADC).
- TermHydrophilic next-generation linkers (TMALIN, Dolaflexin, sulfonyl-pyrimidine, PEG-containing)
Shares Drug efflux pumps (ABC transporters), Sacituzumab tirumotecan, Antibody-drug conjugate (ADC).
- TechnologyAntibody-oligonucleotide conjugates
Shares Degrader-antibody conjugate (DAC), Antibody-drug conjugate (ADC).
- IdeaFlush dormant cells out of bone marrow, then kill them
Shares T-cell engagers (bispecific), Antibody-drug conjugate (ADC), Triple-negative breast cancer (TNBC).
- IdeaAlpha radioligands after ADC failure
Shares Radio-antibody & radio-ADC, Antibody-drug conjugate (ADC), Triple-negative breast cancer (TNBC).
- PersonMax S. Wicha
Shares Epithelial–mesenchymal transition & drug efflux, Triple-negative breast cancer (TNBC).
- CompanySichuan Kelun-Biotech
Shares Sacituzumab tirumotecan, Triple-negative breast cancer (TNBC).
- PairingTROP2 PET → TROP2 ADC selection
Shares Sacituzumab tirumotecan, Antibody-drug conjugate (ADC), Triple-negative breast cancer (TNBC).